Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Pharmacist Barbara Violo holds a vial of the Oxford-AstraZeneca COVID-19 vaccine at the Junction Chemist, an independent pharmacy, in Toronto, March 12, 2021.

Nathan Denette/The Canadian Press

Health Canada’s chief medical adviser says there is no scientific explanation to suggest a link between the Oxford-AstraZeneca COVID-19 vaccine and blood clots.

Dr. Supriya Sharma says Health Canada has a “really low threshold” for adverse events that could trigger a pause in the use of a vaccine and wouldn’t hesitate to do so if something warranted it.

But she says the science is not there to suggest the Oxford-AstraZeneca vaccine could be the reason some patients in Europe developed blood clots after they received it.

Story continues below advertisement

“There’s not a good biological explanation about why a vaccine of this type, injected into a muscle, would cause that kind of adverse event,” said Sharma, in an interview with The Canadian Press.

Denmark, Iceland, Norway and Bulgaria are among almost a dozen European nations that paused the use of Oxford-AstraZeneca’s vaccine this week – either entirely or specific batches of it – after reports of some patients developing blood clots afterward. None of them said there was evidence of a link, but that the pause was out of an abundance of caution pending a review.

Austria stopped using a doses from a batch of the vaccine earlier this week after two reports of blood clots, but experts there concluded neither was related to the vaccine. Austria’s chancellor, Sebastian Kurz, said Friday he would be willing to get the shot himself to show how much trust he has in it.

Many other countries, including Germany, France, Poland, Nigeria, the United Kingdom and Canada, are sticking with AstraZeneca injections, citing a lack of any evidence showing a link.

The vaccine has been authorized in 74 countries, and by the World Health Organization, and 16 million doses have been injected in the U.K. and Europe alone.

Canada approved it Feb. 26, and the first 500,000 doses were distributed to provinces this week, just as the blood-clot concerns began to go public.

Lucilia Pato, who got her first dose Friday morning at the Junction Chemist in west Toronto, said news that some European countries had stopped using AstraZeneca’s vaccine for now initially gave her pause.

Story continues below advertisement

“I was (worried) when I heard about it yesterday but this morning I heard positive things about it, so you know what, I was willing to take my chance,” she said.

The European Medicines Agency, which regulates new drugs for the European Union, said in a statement Thursday it was not suspending its authorization for AstraZeneca’s vaccine.

“There is currently no indication that vaccination has caused these conditions, which are not listed as side-effects with this vaccine,” the EMA said.

Sharma said reviews of adverse events are normal following the release of a new drug or vaccine.

“Once the vaccines are used in the wild, and by millions of people, these things will come up,” she said. “So we’re already in a system where we’re expecting things to pop up and that’s why we have these vigilance systems to be able to detect it.”

Sharma said the first question always to be asked is if there is something scientific to explain a link between an adverse event and a vaccine.

Story continues below advertisement

“And when we’re looking at the AstraZeneca vaccine, as an example, there’s not in this case,” she said.

She said regulators also ask whether the number of patients experiencing the effect is higher than what might normally be seen in the population and whether there is some other factor common to all the patients with the issue.

The answer to each question here is also no.

Finally, Sharma said regulators will consider the possibility of a manufacturing mistake with a particular batch. While there is no evidence of that in Europe either, Canada’s doses of the Oxford-AstraZeneca vaccine are also not coming from the same source as Europe’s.

The doses of the vaccine currently being used in Canada were produced at the Serum Institute of India.

Canada has authorized four distinct vaccines for COVID-19, and almost 2.8 million doses have been injected.

Story continues below advertisement

Sharma said thus far, none has produced “adverse events” in Canada that were either unexpected or more frequent than expected.

She said Health Canada won’t be slow to act on safety concerns. The people making these decisions are aware it’s not just Canadians as a whole, but themselves and their loved ones who will be getting the same vaccines.

“These are our fathers, brothers, sisters, mothers,” she said. “We want to make sure that we’re doing the best for all of them as well.”

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies